pembrolizumab and cetuximab

DRUG2 trials

Sponsors

Commonwealth Healthcare Corporation, Peter Brett, MD

Conditions

Betel-nut-associated Oral CarcinomaOral Squamous Cell Carcinoma (OSCC)

Phase 2

Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma

Not yet recruitingNCT07733466

Peter Brett, MDBetel-nut-associated Oral Carcinoma

Start: 2026-08-15End: 2031-06-01Target: 20Updated: 2026-08-10

Unknown Phase

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

CompletedNCT07015333

Commonwealth Healthcare CorporationOral Squamous Cell Carcinoma (OSCC)

Start: 2020-03-01End: 2024-12-01Updated: 2025-06-11